Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Lukáš Bajer"'
Autor:
Dagmar Schierová, Jan Březina, Jakub Mrázek, Kateřina Olša Fliegerová, Simona Kvasnová, Lukáš Bajer, Pavel Drastich
Publikováno v:
Cells, Vol 9, Iss 10, p 2283 (2020)
Ulcerative colitis (UC) is an inflammatory bowel disease, and intestinal bacteria are implicated in the pathogenesis of this disorder. The administration of aminosalicylates (5-ASA) is a conventional treatment that targets the mucosa, while fecal mic
Externí odkaz:
https://doaj.org/article/69edf05d7cf94a6aa4f4d5f76eeb099c
Autor:
Lukáš Bajer
Publikováno v:
Gastroenterologie a hepatologie. 76:296-301
disease (IBD). CD has progressive character and is associated with the development of various complications leading to potentially serious bowel damage (BD). Early stage of Crohn’s disease (eCD) is characterized by a specific immune response and re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec05aff58cbf179a4a089d85458bc82e
https://doi.org/10.48095/ccgh2022296
https://doi.org/10.48095/ccgh2022296
Publikováno v:
Clinical Endoscopy, Vol 57, Iss 2, Pp 203-208 (2024)
Background/Aims Upper gastrointestinal bleeding (UGIB) is the most common GI condition requiring hospitalization. The present study aimed to evaluate the safety and feasibility of using the PillSense system (EnteraSense Ltd.), a novel diagnostic tool
Externí odkaz:
https://doaj.org/article/ce6371976f86493e86f7c09b66b98182
Autor:
Peter Mačinga, Darina Gogová, Klára Chmelová, Lukáš Bajer, Soňa Fraňková, Jan Sperl, Julius Spicak, Tomáš Hucl
Publikováno v:
Pancreatology. 19:S58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5448586f0232fbda0f9b220df3557e3
https://doi.org/10.1016/j.pan.2019.05.148
https://doi.org/10.1016/j.pan.2019.05.148
Autor:
Stepan Coufal, Miloslav Kverka, Jakub Kreisinger, Tomas Thon, Filip Rob, Martin Kolar, Zuzana Reiss, Dagmar Schierova, Klara Kostovcikova, Radka Roubalova, Lukas Bajer, Zuzana Jackova, Martin Mihula, Pavel Drastich, Jana Tresnak Hercogova, Michaela Novakova, Martin Vasatko, Milan Lukas, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska
Publikováno v:
Journal of Immunology Research, Vol 2023 (2023)
Background. Tumor necrosis factor-alpha (TNF-α) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However, approximately every third IBD patient does not respond to this therapy in the long term, which de
Externí odkaz:
https://doaj.org/article/65bf846ae46d4d019cc3d1fd3e4f4af7
Autor:
Zuzana Reiss, Filip Rob, Martin Kolar, Dagmar Schierova, Jakub Kreisinger, Zuzana Jackova, Radka Roubalova, Stepan Coufal, Martin Mihula, Tomas Thon, Lukas Bajer, Michaela Novakova, Martin Vasatko, Klara Kostovcikova, Natalie Galanova, Milan Lukas, Miloslav Kverka, Jana Tresnak Hercogova, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 12 (2023)
Crohn’s disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel disease (IBD), where the role of gut but not skin dysbiosis is well recognized. Inhibitors of TNF have been successful in IBD treatment, but up to a quarter of pat
Externí odkaz:
https://doaj.org/article/5f297a06b11e4563ad6ccd1dbdc90bc1
Autor:
Filip Rob, Dagmar Schierova, Zuzana Stehlikova, Jakub Kreisinger, Radka Roubalova, Stepan Coufal, Martin Mihula, Zuzana Jackova, Miloslav Kverka, Tomas Thon, Klara Kostovcikova, Lukas Bajer, Pavel Drastich, Jana Tresnak Hercogova, Michaela Novakova, Martin Kolar, Martin Vasatko, Milan Lukas, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska
Publikováno v:
PLoS ONE, Vol 17, Iss 12, p e0277576 (2022)
BackgroundUstekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn's disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab on the immune system, we inv
Externí odkaz:
https://doaj.org/article/1ce2e1563132443fabce1df4c3d02de5
Autor:
Dagmar Schierova, Radka Roubalova, Martin Kolar, Zuzana Stehlikova, Filip Rob, Zuzana Jackova, Stepan Coufal, Tomas Thon, Martin Mihula, Martin Modrak, Miloslav Kverka, Lukas Bajer, Klara Kostovcikova, Pavel Drastich, Jana Hercogova, Michaela Novakova, Martin Vasatko, Milan Lukas, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska
Publikováno v:
Cells, Vol 10, Iss 11, p 3188 (2021)
Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composi
Externí odkaz:
https://doaj.org/article/8eaa98d5e195490994072169e9a9f0b2
Autor:
Stepan Coufal, Natalie Galanova, Lukas Bajer, Zuzana Gajdarova, Dagmar Schierova, Zuzana Jiraskova Zakostelska, Klara Kostovcikova, Zuzana Jackova, Zuzana Stehlikova, Pavel Drastich, Helena Tlaskalova-Hogenova, Miloslav Kverka
Publikováno v:
Cells, Vol 8, Iss 7, p 719 (2019)
Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC-IBD), share three major pathogenetic mechanisms of inflammatory bowel disease (IBD)-gut dysbiosis, gut barrier fa
Externí odkaz:
https://doaj.org/article/7cc9c5bb1ba74f3f80667a585e361bd6